The disintegrin domain of ADAM17 antagonises fibroblast carcinoma cell interactions

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1793-1800

  Trad, Ahmad ^a   Riese, Michel ^a   Shomali, Mohammad ^a   Hedeman, Nina ^a   Effenberger, Timo ^a   Grötzinger, Joachim ^a   Lorenzen, Inken ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

ADAM17; Disintegrin domain; Integrin; Metalloprotease; Metastases

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; DISINTEGRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADAM PROTEINS; CARCINOMA; CELL COMMUNICATION; CELL LINE, TUMOR; DISINTEGRINS; FIBROBLASTS; HUMANS; PROTEIN STRUCTURE, TERTIARY; TUMOR MICROENVIRONMENT;

EID: 84876002140     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1864     Document Type: Article

References (43)

1. Brocker CN, Vasiliou V and Nebert DW: Evolutionary divergence and functions of the ADAM and ADAMTS gene families. Hum Genomics 4: 43-55, 2009.
2. White JM: ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 15: 598-606, 2003. (Pubitemid 37176969)
3. Takeda S: Three-dimensional domain architecture of the ADAM family proteinases. Semin Cell Dev Biol 20: 146-152, 2009.
4. Liu H, Shim AH and He X: Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: insights on ADAM function. J Biol Chem 284: 29077-29086, 2009.
5. Janes PW, Saha N, Barton WA, et al: Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123: 291-304, 2005. (Pubitemid 41457218)
6. Reiss K and Saftig P: The 'a disintegrin and metalloprotease' (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 20: 126-137, 2009.
7. Bax DV, Messent AJ, Tart J, et al: Integrin alpha5beta1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells. J Biol Chem 279: 22377-22386, 2004. (Pubitemid 38679435)
8. McGinn OJ, English WR, Roberts S, Ager A, Newham P and Murphy G: Modulation of integrin alpha4beta1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration. Cell Biol Int 35: 1043-1053, 2011.
9. Saha A, Backert S, Hammond CE, Gooz M and Smolka AJ: Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase alpha subunit. Gastroenterology 139: 239-248, 2010.
10. Gooz P, Dang Y, Higashiyama S, Twal WO, Haycraft CJ and Gooz M: A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by alpha5beta1 integrin in kidney mesangial cells. PLoS One 7: e33350, 2012.
11. Milla ME, Leesnitzer MA, Moss ML, et al: Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). J Biol Chem 274: 30563-30570, 1999.
12. Lorenzen I, Trad A and Grötzinger J: Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun 415: 330-336, 2011.
13. Reddy P, Slack JL, Davis R, et al: Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275: 14608-14614, 2000. (Pubitemid 30339751)
14. Tape CJ, Willems SH, Dombernowsky SL, et al: Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci USA 108: 5578-5583, 2011.
15. Lorenzen I, Lokau J, Düsterhöft S, et al: The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 586: 1093-1100, 2012.
16. Smith KM, Gaultier A, Cousin H, Alfandari D, White JM and DeSimone DW: The cysteine-rich domain regulates ADAM protease function in vivo. J Cell Biol 159: 893-902, 2002. (Pubitemid 36008370)
17. Soond SM, Everson B, Riches DW and Murphy G: ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 118: 2371-2380, 2005. (Pubitemid 40873077)
18. Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 29: 258-289, 2008.
19. Kommaddi RP, Thomas R, Ceni C, Daigneault K and Barker PA: Trk-dependent ADAM17 activation facilitates neurotrophin survival signaling. FASEB J 25: 2061-2070, 2011.
20. McGowan PM, McKiernan E, Bolster F, et al: ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 19: 1075-1081, 2008. (Pubitemid 351796332)
21. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N and Duffy MJ: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 13: 2335-2343, 2007. (Pubitemid 46698582)
22. Tanaka Y, Miyamoto S, Suzuki SO, et al: Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 11: 4783-4792, 2005. (Pubitemid 41557199)
23. Rosso O, Piazza T, Bongarzone I, et al: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246-1253, 2007.
24. Blanchot-Jossic F, Jarry A, Masson D, et al: Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207: 156-163, 2005. (Pubitemid 41404146)
25. Dijkstra A, Postma DS, Noordhoek JA, et al: Expression of ADAMs ('a disintegrin and metalloprotease') in the human lung. Virchows Arch 454: 441-449, 2009.
26. Badoual C, Bouchaud G, Agueznay Nel H, et al: The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 68: 3907-3914, 2008.
27. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8: 1045-1054, 2009.
28. Trad A, Hedemann N, Shomali M, Pawlak V, Grotzinger J and Lorenzen I: Development of sandwich ELISA for detection and quantification of human and murine a disintegrin and metalloproteinase 17. J Immunol Methods 371: 91-96, 2011.
29. Trad A, Hansen HP, Shomali M, et al: ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates. Cancer Immunol Immunother: Sep 1, 2012 (Epub ahead of print).
30. Yamamoto K, Trad A, Baumgart A, et al: A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 445: 135-144, 2012.
31. Zigrino P, Nischt R and Mauch C: The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts. J Biol Chem 286: 6801-6807, 2011.
32. Chalaris A, Rabe B, Paliga K, et al: Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110: 1748-1755, 2007. (Pubitemid 47443884)
33. Jovic M, Naslavsky N, Rapaport D, Horowitz M and Caplan S: EHD1 regulates beta1 integrin endosomal transport: effects on focal adhesions, cell spreading and migration. J Cell Sci 120: 802-814, 2007. (Pubitemid 46523482)
34. Chalaris A, Adam N, Sina C, et al: Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207: 1617-1624, 2010.
35. Baumgart A, Seidl S, Vlachou P, et al: ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res 70: 5368-5378, 2010.
36. Sternlicht MD and Sunnarborg SW: The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia 13: 181-194, 2008.
37. Kuramochi H, Nakajima G, Kaneko Y, et al: Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer 12: 88, 2012.
38. Toquet C, Colson A, Jarry A, et al: ADAM15 to alpha5beta1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int J Cancer 130: 278-287, 2012.
39. Lucas N and Day ML: The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. J Cell Biochem 106: 967-974, 2009.
40. Desiderio UV, Zhu X and Evans JP: ADAM2 interactions with mouse eggs and cell lines expressing alpha4/alpha9 (ITGA4/ITGA9) integrins: implications for integrin-based adhesion and fertilization. PLoS One 5: e13744, 2010.
41. Kornfeld JW, Meder S, Wohlberg M, et al: Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer 104: 138-145, 2011.
42. Gooz M: ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45: 146-169, 2010.
43. Zheng X, Jiang F, Katakowski M, Lu Y and Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog 51: 150-164, 2012.